VERO E6

VERO E6

Cat.No.: CSC-C9140W

Species: Monkey

Source: Kidney

Morphology: epithelial

Cell Type: Epithelial Cell

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C9140W
Description
This line is a clone of VERO 76. It was cloned by the dilution method into microtiter plates in 1979 by P.J. Price.­ Plaques are also produced.
Species
Monkey
Source
Kidney
Recommended Medium
SuperCult® VERO E6 medium
Morphology
epithelial
Cell Type
Epithelial Cell
Disease
Normal
Storage and Shipping
liquid nitrogen vapor phase
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

VERO E6, also known as Vero C1008, is a continuous epithelial cell line derived from the kidney of an African green monkey (Chlorocebus sabaeus). It is a clonal subline of VERO 76, established in 1979 by P.J. Price through limiting dilution.

The defining advantage of VERO E6 lies in its exceptional susceptibility to a broad spectrum of viruses, particularly emerging pathogens. It is a primary cell culture model for SARS-CoV and SARS-CoV-2, supporting high-titer viral replication. The line is also permissive to Ebola, Marburg, Lassa, Junin, Machupo, Zika, West Nile, yellow fever, rabies, reovirus, and Japanese encephalitis viruses. When infected with hemorrhagic fever viruses, it exhibits clear cytopathic effects and plaque formation.

This high susceptibility is attributed to a genomic deletion that renders the cells incapable of producing type I interferons (IFN-α/β), thereby preventing an effective innate antiviral response. Unlike other Vero sublines that are heterozygous for the ACE2 receptor, VERO E6 harbors only a single allele due to X chromosome loss, a feature that may influence its interaction with ACE2-dependent viruses. VERO E6 exhibits contact inhibition post-confluence and is suitable for supporting slow-replicating viruses. These attributes establish VERO E6 as an indispensable platform for emerging infectious disease research.

Probenecid Treatment Inhibits Replication of the Edmonston Measles Virus Strain in Vero Cells

This study examined the efficacy of probenecid treatment before and after measles virus (MeV) infection (MOI = 0.1) of VeroE6 and Vero-SLAM at 24, 48, and 72 hpi. The 24 hpi time point did not show measurable virus plaques; however, peak detectable virus plaque numbers in both VeroE6 and Vero-SLAM cells occurred at 48 hpi (Fig. 1). High plaque numbers were evident at 72 hpi; however, the plaques were not countable because MeV replication in untreated VeroE6 and Vero-SLAM cells destroyed the cell lawns. The values shown below represent the results of 3 independent experiments and 3 replicas/experiment. The study described below examined VeroE6 cells infected (MOI = 0.1) with Edmonston MeV and treated with probenecid. Effective IC50 values for VeroE6 cells that were (A1) prophylactically treated with probenecid 24 h before infection with Edmonston MeV (MOI of 0.1), or (A2) treated 1 h after infection with probenecid, were obtained at the concentrations shown in Fig. 1A.

(A) VeroE6 cells were (A1) prophylactically treated with probenecid 24 h before infection with Edmonston MeV (MOI = 0.1), or (A2) treated 1 h after infection with probenecid at the specified concentrations. (B) is a representative well from a 6-well MeV plaque assay of VeroE6 cells from uninfected, MeV-infected, or MeV-infected 1 µM probenecid-treated VeroE6 cells.
Fig. 1. Probenecid treatment can inhibit the replication of Edmonston MeV strain in VeroE6 cells (Murray, Jackelyn, David E. Martin, and Ralph A. Tripp. 2025).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products